enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Lenalidomide - Wikipedia

   en.wikipedia.org/wiki/Lenalidomide

   Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]

3. Does Medicare cover genetic testing? - AOL

   www.aol.com/lifestyle/does-medicare-cover...

   Medicare Part B covers various genetic tests, such as those to assess certain cancer risks or diagnose genetic conditions, if a healthcare professional deems them medically necessary and the ...

4. Multiple myeloma - Wikipedia

   en.wikipedia.org/wiki/Multiple_myeloma

   MGUS is a relatively stable condition afflicting 3% of people aged 50 and 5% of people aged 70; it progresses to multiple myeloma at a rate of 0.5–1% cases per year; smoldering multiple myeloma does so at a rate of 10% per year for the first 5 years, but then falls off sharply to 3% per year for the next 5 years and thereafter to 1% per year.

5. Does Medicare Cover Genetic Testing? - AOL

   www.aol.com/lifestyle/does-medicare-cover...

   A Medicare-approved doctor must confirm that you have symptoms or an increased risk of developing the condition. Medicare covers genetic testing for certain conditions like cancer or to track the ...

6. What does Medicare Part A cover? Here’s everything you need ...

   www.aol.com/finance/does-medicare-part-cover...

   Medicare Part A helps cover more than just the cost of being in a hospital when you’re 65 or older. Part A also sometimes covers skilled facility care, home health care and hospice care ...

7. Elotuzumab - Wikipedia

   en.wikipedia.org/wiki/Elotuzumab

   The objective of the study was to determine if the addition of elotuzumab with lenalidomide and dexamethasone would increase progression-free survival in patients with refractory multiple myeloma. [10] [11] This randomized, open-label, phase 3, multicenter trial studied patients 18 years and older with multiple myeloma and measurable disease. [10]